Bridging between cancer conferences

For all the breathless hype and attention focused on antibody-drug conjugates (ADCs) of late, you might well be forgiven in thinking other modalities have been broadly abandoned or forgotten completely.

This isn’t actually the case since there are quite a few developments on the bispecific front, which are quietly moving along and showing some intriguing data in certain areas.

As we bridge between World Lung and the ESMO meeting this weeknd, this is a good opportunity to take a look at some of the progress being made off many people’s radar…

To learn more from our latest oncology review and get a heads up on key cancer research insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by